HLS Therapeutics Inc. (TSE:HLS – Get Rating)’s stock price shot up 2.6% on Monday . The stock traded as high as C$6.37 and last traded at C$6.37. 1,030 shares were traded during mid-day trading, a decline of 96% from the average session volume of 24,491 shares. The stock had previously closed at C$6.21.
HLS Therapeutics Stock Performance
The firm’s 50 day simple moving average is C$7.93 and its 200 day simple moving average is C$8.97. The firm has a market capitalization of C$206.07 million, a price-to-earnings ratio of -6.37 and a beta of 0.86. The company has a debt-to-equity ratio of 77.68, a quick ratio of 1.01 and a current ratio of 1.42.
HLS Therapeutics Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, June 15th will be given a dividend of $0.05 per share. The ex-dividend date is Thursday, April 27th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 3.14%. HLS Therapeutics’s dividend payout ratio (DPR) is -20.00%.
About HLS Therapeutics
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.
Featured Stories
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Splunk Stock is an AI-Powered Enterprise SEIM Play
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
